ADCC	antibody-dependent cytotoxic effects
AML	acute myelocytic leukemia
ADCs	antigen-drug conjugates
ADCP	antibody-dependent cell-mediated phagocytosis
BET	bromodomain and extraterrestrial
CRT	Cell surface calreticulin
CDC	complement-dependent cytotoxic effects
DAMPs	danger associated molecular patterns
DLT	dose-limiting toxicity
EGF	epidermal growth factor
EV	extracellular vesicles
EXO-CD24	Exosomal overexpression of CD24
GVHD	raft versus host disease
HCC	hepatocellular carcinoma
HNSCC	head and neck squamous cell carcinoma
IAP	integrin-associated protein
ITIM	immunoreceptor tyrosine inhibitory motif
IR	interventional radiotherapy
LILRB1	leukocyte immunoglobulin-like receptor B
MHC-1	major histocompatibility complex class I
MDS	myelodysplastic syndrome
MICA	major histocompatibility complex class I-associated chain A
NK cells	natural killer cells
NHL	non-Hodgkin’s lymphoma
NSCLC	non-small cell lung cancer
RBCS	red blood cells
SCLC	small cell lung cancer
SIRPα	signal regulatory protein α
SHPS-1	protein tyrosine phosphatase substrate 1
SUSAR	unexpected serious adverse effects
SLAMF7	Signaling lymphocyte activation molecular family 7
TAM	tumor-associated macrophages
TNBC	triple-negative breast cancer
TGFBR2	growth factor beta receptor 2
TGFB1	growth factor beta 1
VEGF	Vascular endothelial growth factor
VAP-1	vascular adhesion protein-1